OBN is the not-for-profit Membership organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Our 400-plus Member companies are located across the Golden Triangle and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland, benefiting from our networking, partnering, purchasing, training, advising and advocacy activities.
OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model.
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early-stage start-ups, leading academic groups, and not-for-profit companies.
ImmunoINSIGHTS is Oncimmune’s service to the life science industry, built off the company’s proprietary autoantibody profiling technology. Underpinned by Oncimmune’s proprietary high throughput immunogenic protein library, one of the largest in the world, covering more than 95% of known human antigens, the technology can be utilised for profiling autoantibodies in patients receiving or about to receive treatment. This unique combination of Oncimmune’s core technology and understanding of the immune system enables life-science organisations to optimise drug development, leading to more effective, targeted, as well as safer treatments for patients.
One Nucleus is a Cambridge/London Life Science membership organisation. We support Europe’s largest Life Science cluster encompassing the London-Cambridge-East of England region via knowledge transfer, connectivity, inward investment and growth.
Onyx Scientific is a small molecule CDMO specialising in process R&D, non-GMP scale up and GMP manufacture for clinical trials and commercial. Good chemistry is at the core of everything we do. From our facilities in the UK and US, our teams of chemists will guide your small molecule API through development and manufacturing from the moment a lead molecule is identified, taking it into Phase I studies and right through to commercial manufacture.
Paspigioni is a full-service CRO that offers cost-effective, high-quality clinical trials from Phases I to IV. They also provide medical device studies, often with a rapid start-up.
They operate across 19 emerging markets in Central and Eastern Europe, the Balkans, and Asia, ensuring a competitive edge for their partners. Using a CRO-in-a-box approach, Paspigioni launches and manages trials in different countries and supports biotech and pharma companies with efficient solutions. They guide their partners through new clinical landscapes, offering operational excellence and reliable results. They enable access to untapped patient populations, and provide local market expertise and a clear regulatory path.
Pencil Biosciences is developing a truly innovative gene editing technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. The technology is small, modular in design, and non-CRISPR in composition.
The Pharmaceutical Licensing Group, in the UK, has been established for 30 years and is the professional association for those active in pharmaceutical and biotechnology business development and licensing.
There are around 200 members in the UK and over a 1000 in affiliated groups in Europe, Canada and Japan. All sectors of the industry are represented including multinationals, medium and small pharmaceutical companies, biotechnology, generic and consumer companies.
The PLG is a not-for-profit organisation and is managed by a committee of licensing and business development executives from member companies. Details of the Committee members and how to contact them can be found by following the Committee link.
The PLG organises meetings within local countries, a bi-annual European meeting and a bi-annual International meeting. Details of all meetings can be found on the Events page and by linking to other PLG sites on the European page.
Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments.
They work with partners developing cancer drugs to help them save time and money and achieve better outcomes during pre-clinical and clinical development. They are also developing tools to support cancer treatment in real world settings
Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.
